Navigation Links
BioMarin to Host Research and Development Day June 5th
Date:5/22/2008

NOVATO, Calif., May 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) will host a Research and Development Day for the financial community on Thursday, June 5, 2008 from 7:30 a.m. to 11:30 a.m. at the W New York Hotel in New York City. Members of BioMarin's senior management team will provide an overview of the company's product portfolio, new information about advancements in the research and development pipeline and other ongoing programs. Featured guests will include Dr. Barbara Burton, Professor of Pediatrics, Northwestern University Feinberg School of Medicine and Director, PKU Clinic at Children's Memorial Hospital.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Present at the Bank of America Healthcare Conference
2. BioMarin Announces First Quarter 2008 Financial Results
3. BioMarin to Present at the Morgan Stanley Healthcare Conference
4. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
5. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
6. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
7. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
8. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
9. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
10. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
11. BioMarin to Present at the BioCentury NewsMakers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
(Date:9/22/2014)... Pa. (PRWEB) September 22, 2014 ... rapid diagnostics for the food and beverage industries, ... will be distributed under a non-exclusive agreement by ... and services. , Enartis, an Esseco Group company ... to winemakers in California and other global markets ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3
... Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, ... next,generation of monoclonal antibodies based on its Dynamic ... and Chairman, will,present at the 7th Annual BIO ... Morhet,s thirty-minute presentation to potential investors and,industry partners ...
... Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), NOVATO, Calif., Oct. 28 , ... Q3 2008 ... 190.5% increase Naglazyme Net Product Revenue ... Aldurazyme Net Sales by Genzyme $38.2 ...
... ASA (OSL:DIAG),today announced that it has signed ... panEuropean provider of gene expression-based,diagnostic testing and ... marking scheduled in early2009, DiaGenic will be ... Europe its innovative blood-based,gene-expression diagnostic test for ...
Cached Biology Technology:InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests 2
(Date:9/22/2014)... In 2011 the Society of Environmental Toxicology and ... to identify and prioritize the scientific research needed to ... (PPCPs) in the environment. The effort was extended, ... of the Society,s international journal, Integrated Environmental Assessment ... accompanied by a podcast interviewing the lead author of ...
(Date:9/22/2014)... 22, 2014)The Brain & Behavior Research Foundation ... NARSAD Young Investigator Grants valued at more ... world,s most promising young scientists. Recipients of ... research will seek to identify causes, improve ... disorders that affect one in four people, ...
(Date:9/22/2014)... 22, 2014) Additive manufacturing (AM), or 3D ... production of complex-shaped metal components strong enough for ... errors and distortions, as well as quality standards ... pace with the technology. Engineers at the University ... to develop enhanced modeling and simulation (M&S) technology ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3
... 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization ... to industry, announced today that they have begun a ... for Type 2 Diabetes Mellitus.  The study is being ... daily doses of the investigational medication over periods of ...
... the University of Wisconsin-Madison have made a discovery that, ... may contribute to diseases like Alzheimer,s and Parkinson,s, which ... the brain. With proteins, shape is everything. The ... molecules about a cell, others to provide essential cellular ...
... laboratory work allowed a diverse team of University of Pittsburgh ... Nature Cell Biology that they had solved the mystery ... By discovering a mechanism by which mitochondria tiny structures ... they are damaged and need to be eliminated, the Pitt ...
Cached Biology News:Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2Zinc, proteins, and an essential cellular balancing act 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 3
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: